Iovance Biotherapeutics (IOVA) Operating Expenses (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Operating Expenses of $152.5 million for Q1 2026, down 10.6% year-over-year from $170.5 million in Q1 2025, and down 4.84% quarter-over-quarter from $160.2 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Operating Expenses (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Operating Expenses for 16 consecutive years, with $152.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Expenses fell 10.6% year-over-year to $152.5 million; the TTM figure through Mar 2026 stood at $648.8 million (up 6.11% YoY), while the FY2025 annual figure was $666.9 million, up 19.22% from the prior year.
- Operating Expenses declined to $152.5 million in Q1 2026 per IOVA's latest filing, from $160.2 million in the prior quarter.
- Across five years, Operating Expenses topped out at $173.7 million in Q2 2025 and bottomed at $91.7 million in Q1 2022.
- Historically, Operating Expenses has averaged $131.7 million across 5 years, with a median of $121.7 million in 2023.
- Annual changes were most pronounced in 2025 — Operating Expenses surged 44.0% — and 2026, when it declined 10.6%.
- Iovance Biotherapeutics' Operating Expenses stood at $107.0 million in 2022, then gained by 13.74% to $121.7 million in 2023, then soared by 31.65% to $160.3 million in 2024, then fell by 0.02% to $160.2 million in 2025, then slipped by 4.84% to $152.5 million in 2026.
- Business Quant data shows IOVA's Operating Expenses at $152.5 million in Q1 2026, $160.2 million in Q4 2025, and $162.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | 151.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 151.22 Mn |
| Mar 31, 2026 | 152.47 Mn |
| Dec 31, 2025 | 160.23 Mn |
| Sep 30, 2025 | 162.36 Mn |
| Jun 30, 2025 | 173.73 Mn |
| Mar 31, 2025 | 170.55 Mn |
| Dec 31, 2024 | 160.27 Mn |
| Sep 30, 2024 | 147.62 Mn |
| Jun 30, 2024 | 133.02 Mn |
| Mar 31, 2024 | 118.44 Mn |
| Dec 31, 2023 | 121.74 Mn |
| Sep 30, 2023 | 118.83 Mn |
| Jun 30, 2023 | 110.32 Mn |
| Mar 31, 2023 | 110.86 Mn |
| Dec 31, 2022 | 107.04 Mn |
| Sep 30, 2022 | 100.40 Mn |
| Jun 30, 2022 | 99.73 Mn |
| Mar 31, 2022 | 91.71 Mn |
| Dec 31, 2021 | 99.47 Mn |
| Sep 30, 2021 | 86.24 Mn |